Allergenis

Allergenis

Closed: Aug. 2023

About this raise

Allergenis, with a valuation of $40 million, is raising funds on StartEngine. The company uses cutting-edge systems biology and data analytics to provide next-generation food allergy testing. The Allergenis system of testing determines tolerance levels, allergic status, and reaction severity to provide a better-informed quality of life. Currently, Allergenis provides peanut allergic status and threshold testing in 49 states and Washington, DC, and plans to launch milk allergy testing in 2023 and egg allergy testing in 2024. Jim Garner founded Allergenis in September 2017. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1.24 million. The campaign proceeds will be used for sales and marketing, clinical operations, research and development, and general and administrative expenses.

Expand

Investment Overview

Invested this round: $560,602

Deal Terms

Total Commitments

Platform
StartEngine
Start Date
04/24/2023
Close Date
08/21/2023
Min. Goal
$10,000
Max Goal
$1,235,000
Min. Investment

$250

Security Type

Equity - Common

Company Stage

Growth Stage

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$5.00

Pre-Money Valuation

$40,000,005

Company & Team

Company

Year Founded
2017
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
High
Capital Intensity
Low
Location
NEW YORK, New York
Business Type
Growth
Company Website
Visit Website

Team

Employees
30
Prior Founder Exits?
Yes
Founder Name
John Simons
Title
Board Member
Founder Name
Russ Fein
Title
CFO

Financials

 Revenue -72.5% YoY
$74,140
as of FY2022
 Monthly Burn
$412,716
as of FY2022
 Runway
0.1 months
as of FY2022

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$74,140

$269,597

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-4,952,594

$-3,422,933

Summary Balance Sheet

FY 2022 FY 2021

Cash

$31,203

$19,639

Accounts Receivable

$4,395

$10,000

Total Assets

$454,522

$368,099

Short-Term Debt

$5,157,434

$1,496,119

Long-Term Debt

$1,050,000

$2,942,000

Total Liabilities

$6,207,434

$4,438,119

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$19,000,000
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
08/21/2023 StartEngine $40,000,005 $560,602 Equity - Common Funded RegCF
Create a free account today to gain access to Kingscrowd analytics.
Add to portfolio
Allergenis on StartEngine 2023
Platform: StartEngine
Security Type: Equity - Common
Valuation: $40,000,005
Price per Share: $5.00

Follow company

Follow Allergenis on StartEngine 2023

Buy Allergenis's Deal Report

Warning: according to the close date for this deal, Allergenis may no longer be accepting investments.

Allergenis Deal Report

Get Kingscrowd's comprehensive report on Allergenis including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Allergenis is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Allergenis deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge